NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia
Pharmaceutical Technology
OCTOBER 7, 2024
The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.
Sat.Oct 05, 2024 - Fri.Oct 11, 2024
304 
New data underline cancer risk of Bluebird therapy for brain disease
Bio Pharma Dive
OCTOBER 10, 2024
Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
Bio Pharma Dive
OCTOBER 10, 2024
Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.
Deltaclinical is participating Bio Japan from 9 – 11 OCT.
Deltaclinical
OCTOBER 7, 2024
Would you like to learn more about our services? Visit us at booth C-24. We are happy to welcome you! But first, our CEO Geert Briers will attend the EU-Japan center conference in Osaka from 7 – 8 OCT.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
October 9, 2024: In This Week’s PCT Grand Rounds, Early Diagnosis and Treatment of COPD
Rethinking Clinical Trials
OCTOBER 9, 2024
Dr. Shawn Aaron In this Friday’s PCT Grand Rounds, Shawn Aaron of the University of Ottawa will present “Early Diagnosis and Treatment of Asthma and COPD.” The Grand Rounds session will be held on Friday, October 11, 2024, at 1:00 pm eastern. Aaron is a professor of medicine at the University of Ottawa and the director of the Canadian Respiratory Research Network.
EMA starts review into hair loss drugs about potential link to suicidal thoughts
Pharmaceutical Technology
OCTOBER 7, 2024
The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of finasteride.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
AstraZeneca heads to regulators after Airsupra asthma trial stops early thanks to 'overwhelming efficacy'
Fierce Pharma
OCTOBER 7, 2024
After winning a first-in-class nod for its two-drug inhaler Airsupra l | After winning a first-in-class nod for its two-drug inhaler Airsupra last January, AstraZeneca is bolstering the rescue treatment’s clinical package with new data showing it can cut the risk of asthma exacerbations regardless of patients’ disease severity.
FluoGuide submits clinical trial application for head and neck cancer treatment
Pharma Times
OCTOBER 7, 2024
Biotech company moves forward with phase 2 trial for precision cancer surgery
Could preventative care save the future of the NHS?
Pharmaceutical Technology
OCTOBER 9, 2024
As a major report highlights the challenges of a struggling NHS, the call for preventative care is growing in the UK.
Ex-Pfizer execs ‘threatened’ for supporting plans to shake up company, Starboard says
Bio Pharma Dive
OCTOBER 10, 2024
In a letter to Pfizer’s board, the activist investor claimed former CEO Ian Read and CFO Frank D’Amelio were pressured to abandon a Starboard-led attempt to change the company’s direction.
Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list
Fierce Pharma
OCTOBER 8, 2024
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, claiming its action to remove Eli Lilly’s Mounjaro and Zepbound from its drug shortage list is a “reckless and arbitrary decision—lacking any semblance of lawful process.” In declaring the end of the shortage, the FDA has halted the ability of compounding pharmacies to manufacture the in-demand products.
October 8, 2024: HCSRN Calls for Abstracts and Panel Presentations for 2025 Annual Conference
Rethinking Clinical Trials
OCTOBER 8, 2024
The Health Care Systems Research Network (HCSRN) is accepting abstract submissions and panel proposals for its 2025 Annual Conference until December 9, 2024. This year’s meeting will be held in St. Louis, Missouri, from April 8 to 10, 2025. Information about conference registration, preconference workshops, and accommodations is also available. Early-bird registration is open through February 21.
Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status
Pharmaceutical Technology
OCTOBER 8, 2024
The Phase III trials will evaluate survodutide in metabolic dysfunction-associated steatohepatitis (MASH), fibrosis and cirrhosis.
Sanofi may have found a buyer for its consumer health business
Bio Pharma Dive
OCTOBER 11, 2024
The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Johnson & Johnson myeloma drug recommended for NHS use
Pharma Times
OCTOBER 10, 2024
Teclistamab offers hope for patients exhausting treatment options
Roche burnishes breast cancer portfolio with FDA approval for Itovebi, a threat to Novartis and AZ
Fierce Pharma
OCTOBER 10, 2024
As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2-billion-Swiss-francs luster to the once high-flying portfolio. | As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2-billion-Swiss-francs luster to the once high-flying portfolio.
City Therapeutics launches with $135m Series A funding
Pharmaceutical Technology
OCTOBER 9, 2024
City Therapeutics has announced its launch accompanied by a $135m Series A financing to lead advancements in RNAi-based medicine.
Scholar Rock scores with ‘surprise’ success in SMA drug study
Bio Pharma Dive
OCTOBER 7, 2024
Phase 3 findings could position the biotech’s therapy to become part of a “new standard” for SMA, its CEO said, while boosting research into whether it can preserve muscle in people with obesity.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Kyowa Kirin announces positive interim data for lymphoma treatment
Pharma Times
OCTOBER 8, 2024
Real-world studies show effectiveness of mogamulizumab in routine practice
Pfizer, bracing for Hurricane Milton, pledges aid to emergency services and health support
Fierce Pharma
OCTOBER 8, 2024
Editor's Note: Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub in Tampa, Florida, in 2021—is setting out to bolster emergency services, pool donations and ease medical supply needs as Hurricane Milton touches down this week.
Merck unveils €290m biosafety testing facility in Maryland, US
Pharmaceutical Technology
OCTOBER 10, 2024
Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, US.
AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines
Bio Pharma Dive
OCTOBER 9, 2024
The company, which is building a database of biological interactions found in nature, revealed $60 million in funding and a collaboration with David Liu’s lab.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Advancing Precision Care For All
pharmaphorum
OCTOBER 9, 2024
Advancing Precision Care For All with Hakim Yadi from Closed Loop Medicine. Listen to the latest podcast episode featuring insights from a leader in the healthcare industry.
Heart patient goes home hours after live-streamed valve replacement
Pharma Times
OCTOBER 10, 2024
Sheffield cardiologists demonstrate cutting-edge TAVI procedure
Ipsen’s Elafibranor gains MHRA approval for PBC treatment
Pharmaceutical Technology
OCTOBER 9, 2024
Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) in adults.
Using de-identified lab data to find patients, target physicians and expedite treatment
Bio Pharma Dive
OCTOBER 9, 2024
Many pharma companies are now using de-identified lab data to identify potential patients and their physicians in time to impact the patient’s treatment plan. In this Q&A, learn how lab data can be used to increase patient access.
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
Fierce Pharma
OCTOBER 7, 2024
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular Type 2 diabetes drug Ozempic. | Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic, also known as semaglutide, India’s Natco Pharma said.
AI in Action: Accelerating the Drug Discovery Pipeline
Drug Patent Watch
OCTOBER 8, 2024
A recent study published in Drug Discovery Today highlights the potential of artificial intelligence (AI) in revolutionizing drug discovery and development processes[1]. The research, conducted by a team from the University of Cambridge and AstraZeneca, explores how AI can be leveraged to enhance various aspects of pharmaceutical research, from target identification to clinical trials.
Activist investor Starboard cries foul play in exec U-turn at Pfizer
Pharmaceutical Technology
OCTOBER 11, 2024
Starboard has accused Pfizer of “coercive conduct” after executives who initially backed the hedge fund retracted their support.
Lilly names Mount Sinai scientist as first chief AI officer
Bio Pharma Dive
OCTOBER 9, 2024
Thomas Fuchs will lead artificial intelligence initiatives across Lilly, including in drug discovery, clinical trials and manufacturing.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Let's personalize your content